Every Form 4 that Alzamend Neuro, Inc. (ALZN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALZN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALZN filings page.
Alzamend Neuro, Inc. (ALZN) director Milton C. Ault III reported selling 2,000 shares of common stock in open-market transactions on August 26, 2026 at a volume weighted average price of $1.5581 per share, reducing his directly held shares to 0. He continues to report indirect ownership of Alzamend Neuro common stock, including shares held through Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC. Ault calculated a short-swing profit on matchable transactions that he intends to disgorge to Alzamend Neuro under Section 16(b) of the Exchange Act.
Alzamend Neuro, Inc. (ALZN) had an amended insider report from director Milton C. Ault III correcting previously omitted purchases on April 14, 2026. An entity associated with him, Ault Lending, LLC, bought 108,388 shares of common stock at about $1.0047 per share, held indirectly, bringing that entity’s holdings to 116,648 shares. Ault also directly purchased 2,000 shares at a volume weighted average price of $1.0338 per share, with trading that day occurring between $1.00 and $1.05 per share. He is also reported to have indirect holdings of 11,068 shares through Ault Life Sciences, Inc. and 61 shares through Ault Life Sciences Fund, LLC.
Alzamend Neuro, Inc. (ALZN) director Milton C. Ault III reported additional purchases of common stock on April 14, 2026 in an amended Form 4. An affiliated entity, Ault Lending, LLC, bought 108,388 shares at $1.0047 per share, and Ault personally bought 2,000 shares with a volume weighted average price of $1.0338, in open market transactions. Following these transactions, reported holdings include 116,648 indirect shares via Ault Lending, 11,068 indirect shares via Ault Life Sciences, Inc., 61 indirect shares via Ault Life Sciences Fund, LLC, and 2,000 direct shares.
Alzamend Neuro, Inc. (symbol: ALZN) is the issuer of record for a Form 4/A filing submitted to the SEC.
Hyperscale Data, Inc., a director-by-deputization of Alzamend Neuro, Inc., reported that its indirectly controlled subsidiary Ault Lending, LLC received a grant of 7,500 shares of Alzamend’s Series D Convertible Preferred Stock on July 31, 2026 at a reported price of $1,000.00 per share, resulting in indirect holdings of 7,500 preferred shares.
Each Series D share has a stated value of $1,050.00 and is convertible into common stock at a variable Conversion Price. As of August 4, 2026, the Conversion Price was $1.016 per share, so each preferred share was then convertible into approximately 1,033.5 common shares. The filing also lists several existing common stock purchase warrants held indirectly through Ault Lending.
Alzamend Neuro director Milton C. Ault III, through Ault Lending, LLC, acquired 7,500 shares of Series D Convertible Preferred Stock on July 31, 2026 as a grant. Each share has a stated value of $1,050.00 and is convertible into Common Stock at a variable Conversion Price; as of August 4, 2026, each was convertible into approximately 1,033.5 Common shares. The filing also lists indirect holdings of several Common Stock purchase warrants and direct stock options for 100,000 shares at a $2.33 exercise price expiring in 2035.
Alzamend Neuro, Inc. director Milton C. Ault III, through affiliated entities, reported an indirect open-market purchase of 108,388 shares of common stock at $1.0047 per share on April 14, 2026, executed by Ault Lending, LLC.
After this trade, Ault Lending, LLC held 116,648 common shares. Separate indirect holdings disclosed include 11,068 shares held by Ault Life Sciences, Inc. and 61 shares held by Ault Life Sciences Fund, LLC, with Mr. Ault having voting and investment power over these entities’ positions.
Alzamend Neuro (ALZN) reported an insider transaction on a Form 4. A director sold 30 shares of common stock on 10/23/2025 at $2.29 per share (transaction code S). Following the sale, the reporting person beneficially owned 25 shares, held directly. The filing was submitted by one reporting person and shows no derivative securities activity.
Milton C. Ault III, a director of Alzamend Neuro, Inc. (ALZN), reported a series of transactions in early October 2025. On 10/08/2025 he converted Series B convertible preferred shares into 61,743 shares of common stock at a conversion price of $2.32, increasing the indirect holdings reported for Ault Lending, LLC to 130,591 shares. That same day he sold 101,394 shares in open-market transactions at a volume-weighted average price of $2.4376 (trade range $2.42–$2.4634).
On 10/09/2025 he sold an additional 20,397 shares at $2.3234, leaving Ault Lending, LLC with 8,260 indirectly held shares. The filing also shows other indirect holdings: 11,068 shares via Ault Life Sciences, Inc. and 61 shares via Ault Life Sciences Fund, LLC, plus several warrants totaling 23,334 underlying common shares across three warrant issuances.
Milton C. Ault III, a director of Alzamend Neuro, Inc. (ALZN), reported multiple insider transactions in October 2025. He converted Series B preferred shares into 100,000 common shares on 10/03/2025 and again on 10/07/2025, and sold portions of common stock in open-market transactions: 82,033 shares on 10/06/2025 at a VWAP of $2.4535 and 57,379 shares on 10/07/2025 at a VWAP of $2.4914. After these moves, beneficial ownership is reported indirectly through entities including Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC. The filings disclose outstanding warrants and converted preferred stock that underlie additional common shares.
Milton C. Ault III, a director of Alzamend Neuro, Inc. (ALZN), reported multiple transactions in early October 2025. On 10/01/2025 he converted Series B convertible preferred shares into 100,000 shares of common stock at a conversion price of $2.32. On 10/01–10/03/2025 he sold common shares in open-market transactions: 36,777 shares on 10/01 at a VWAP of $2.3487, 20,686 shares on 10/02 at $2.394, and 65,903 shares on 10/03 at a VWAP of $2.4413, totaling 123,366 shares sold.
The Form 4 lists changing beneficial ownership figures tied to Ault-controlled entities: following the conversion Ault Lending is reported with 131,626 shares beneficially owned, which moved to 94,849, then 74,163, and then 8,260 after the sales. Additional holdings are shown for Ault Life Sciences, Inc. (11,068) and Ault Life Sciences Fund, LLC (61), with voting and investment power described in the filing.
Milton C. Ault III, identified as a director and a 10% owner of Alzamend Neuro, Inc. (ALZN), reported multiple sales of the company’s common stock in late September 2025. The filings show sales on 09/26/2025 of 37,738 shares at $2.3145, on 09/29/2025 of 38,324 shares at $2.309, and on 09/30/2025 of 3,566 shares at $2.3334. After those transactions, beneficial ownership reported for the related entities was 73,516 shares (indirect) by Ault Lending, LLC, 35,192 shares (indirect) by Ault Lending, LLC, and 31,626 shares (indirect) by Ault Lending, LLC, respectively. Additional holdings include 11,068 shares held indirectly by Ault Life Sciences, Inc. and 61 shares indirectly by Ault Life Sciences Fund, LLC. The Form 4 is signed by Mr. Ault on 09/30/2025.
Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc. (ALZN), reported multiple transactions in September 2025 affecting both direct and indirect holdings. The filings show open-market dispositions on 09/23/2025 (43,238 shares at $2.3757) and 09/24/2025 (39,140 shares at a $2.3090 VWAP), plus a 09/25/2025 sale of 14,628 shares at $2.3126. On 09/25/2025 Mr. Ault reported conversion of Series B convertible preferred stock into 100,000 common shares at $2.32 per share. The report lists additional holdings indirectly held through related entities (Ault Lending, Ault Life Sciences, and Ault Life Sciences Fund) and warrants and convertible preferred interests held by Ault Lending.
Milton C. Ault III, a director and >10% owner of Alzamend Neuro, Inc. (ALZN), reported multiple transactions in September 2025. On 09/19/2025 he disposed of 77,009 common shares at $2.3485, leaving 8,260 shares beneficially owned indirectly through Ault Lending, LLC. On 09/22/2025 he converted Series B convertible preferred stock into 100,000 common shares at a conversion price of $2.32, bringing indirect beneficial ownership through Ault Lending to 108,260 shares. The filing also discloses additional indirect holdings: 11,068 shares held by Ault Life Sciences, Inc. and 61 shares held by Ault Life Sciences Fund, LLC. Derivative holdings include Series B preferred interests and several warrants held indirectly by Ault Lending, LLC.
Milton C. Ault III, a director and >10% owner of Alzamend Neuro, Inc. (ALZN), reported transactions on 09/17/2025 and 09/18/2025. On 09/17/2025 he converted Series B convertible preferred stock into 100,000 shares of common stock at a conversion price shown as $2.32, resulting in a reported beneficial ownership of 108,260 shares (indirect) held through Ault Lending, LLC. Also on 09/17/2025 he sold 2,121 shares at $2.4535 and on 09/18/2025 he sold 20,870 shares at $2.4673, reducing reported indirect holdings to 85,269 shares. Additional small indirect holdings are reported through Ault Life Sciences, Inc. and Ault Life Sciences Fund, LLC. The Form 4 is signed 09/19/2025.